Venous Thromboembolism in Myotonic Dystrophy Type 1

NACompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

June 11, 2018

Primary Completion Date

March 15, 2023

Study Completion Date

March 15, 2023

Conditions
Myotonic Dystrophy 1
Interventions
BIOLOGICAL

Haemostasis tests

Venipuncture of 30 milliliters of blood. The following tests will be performed: thromboelastography (TEG®), standard tests of coagulation, genetic thrombophilia, lupus anticoagulant, fibrinolysis markers (Alpha-2-antiplasmin, amidolytic activity, plasmin anti-plasmin complexes, Plasminogen Activator Inhibitor-1 (PAI-1) antigen, plasminogen amydolytic activity), and a global test of fibrinolytic activity.

BIOLOGICAL

Monocytes and megacaryocytes culture and RNA extraction

Venipuncture of 60 milliliters of blood. Monocytes and megacaryocytes culture. RNA extraction from monocytes and megacaryocytes.

GENETIC

RNA extraction

RNA extraction from liver tissue

Trial Locations (1)

75014

Service de Cardiologie - Hôpital Cochin, Paris

All Listed Sponsors
collaborator

AFM-Téléthon (Funding)

UNKNOWN

collaborator

Recherche Clinique Paris Descartes Necker Cochin Sainte Anne

OTHER

collaborator

URC-CIC Paris Descartes Necker Cochin

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03424460 - Venous Thromboembolism in Myotonic Dystrophy Type 1 | Biotech Hunter | Biotech Hunter